All In Biotech

Drug Trial Radar · NCT01181986

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

Exenatide and Postprandial Endothelial Dysfunction: Effects and Mechanisms

Last checked: Nov 19, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Aug 2010

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Carl T. Hayden VA Medical CenterFederal agency
Sponsor type
Federal agency
Collaborators
American Diabetes Association; Amylin Pharmaceuticals, LLC.
First posted
Aug 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
All sexes, from 35 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this investigation is to evaluate whether exenatide, a type 2 diabetes medication, will improve the function of the innermost part of the arterial wall called the endothelium after a fat-enriched meal and to determine how this occurs. The results of this study will help to determine and understand a novel action of this group of diabetes medications based on the action of naturally occuring gut substances called incretins. This may have a significant impact on cardiovascular health in patients with early and longstanding diabetes.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Exenatide SCDrug

    Exenatide 5-10 ug sc BID/10 days

  • Exenatide IVDrug

    50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days

  • Placebo SCDrug

    Placebo sc BID/10days

  • Exendin-9Drug

    Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.

  • Placebo IVDrug

    Intravenous infusion for 45 minutes on 1 out of 3 visits

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reactive Hyperemia Index (RHI)Time frame: 0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 & 3 (Sub-study 2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Phoenix VA Medical Center

    Phoenix, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.